A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial. Journal Abstract - Guideline Central

A Neuroimmune Modulator for Alcohol Use Disorder: A Randomized Clinical Trial.

Published: 2025 Apr 01

Authors

, , , , , , , , , , ,

Abstract

The neuroimmune system represents a promising target for novel medications for alcohol use disorder (AUD). Ibudilast is a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE) 3, PDE4, PDE10, and PDE11, and macrophage migration inhibitory factor (MIF).

Source

JAMA network open

Publication Type

Journal Article

Language

English

PubMed ID

40305022

MeSH terms

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.